Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
HBM Holdings Ltd. ( (HK:2142) ) has shared an update.
HBM Holdings Ltd. has entered into an exclusive license agreement with Windward Bio AG, granting them worldwide rights, excluding certain Asian regions, to develop and commercialize the anti-TSLP monoclonal antibody HBM9378/SKB378. This collaboration is expected to bolster HBM’s global cooperation network and enhance the commercial potential of their technology platform, providing a strategic advantage in the market for innovative drug solutions for respiratory conditions.
More about HBM Holdings Ltd.
HBM Holdings Ltd. operates in the biopharmaceutical industry, specializing in the development and commercialization of innovative monoclonal antibodies. The company focuses on creating therapies for immunological conditions, with a significant emphasis on respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
YTD Price Performance: 20.43%
Average Trading Volume: 2,869,174
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$1.69B
For detailed information about 2142 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue